Barclays PLC Increases Stock Position in Liquidia Co. (NASDAQ:LQDA)

Barclays PLC increased its position in Liquidia Co. (NASDAQ:LQDA) by 17.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 117,085 shares of the company’s stock after buying an additional 17,101 shares during the quarter. Barclays PLC owned about 0.14% of Liquidia worth $1,377,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. JPMorgan Chase & Co. raised its holdings in shares of Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after purchasing an additional 210,753 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Liquidia by 9.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company’s stock valued at $5,040,000 after buying an additional 38,313 shares during the period. Bank of New York Mellon Corp lifted its position in Liquidia by 3.3% during the fourth quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company’s stock valued at $2,218,000 after buying an additional 6,034 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Liquidia during the fourth quarter worth approximately $2,681,000. Finally, Legal & General Group Plc increased its position in shares of Liquidia by 6.5% in the fourth quarter. Legal & General Group Plc now owns 83,286 shares of the company’s stock worth $979,000 after acquiring an additional 5,048 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Trading Up 13.2 %

Liquidia stock opened at $15.83 on Friday. The stock has a 50 day moving average of $14.22 and a 200-day moving average of $13.01. The stock has a market cap of $1.35 billion, a P/E ratio of -9.71 and a beta of 0.24. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.81.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities analysts predict that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other news, insider Jason Adair sold 1,856 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the completion of the sale, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 over the last three months. 30.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on LQDA shares. Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).